```
1
       The antibody response to SARS-CoV-2 infection persists over at least 8 months in
 2
      symptomatic patients
 3
      Riccardo Levi<sup>1,2</sup>*, Leonardo Ubaldi<sup>1,2</sup>*, Chiara Pozzi<sup>2</sup>, Giovanni Angelotti<sup>2</sup>, Maria Teresa Sandri<sup>1,2</sup>,
 4
      Elena Azzolini<sup>1,2</sup>, Michela Salvatici<sup>2</sup>, Victor Savevski<sup>2</sup>, Alberto Mantovani<sup>1,2,3</sup> and Maria
 5
      Rescigno<sup>1,2,#</sup>
 6
 7
 8
       <sup>1</sup>Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini, 20072 Pieve
 9
       Emanuele, MI, Italy.
       <sup>2</sup>IRCCS Humanitas Clinical and Research Center, Via Manzoni 56, 20089 Rozzano, MI, Italy.
10
      <sup>3</sup>The William Harvey Research Institute, Queen Mary University of London, London, UK
11
12
       *These authors contributed equally to the work
13
14
15
       <sup>#</sup>Corresponding author
16
17
       E-mail: maria.rescigno@hunimed.eu
18
       Humanitas University
19
       Via Rita Levi Montalcini, 4
       20072 Pieve Emanuele (MI) Italy
20
21
22
23
24
25
26
27
```

29 Abstract

30

31 The factors involved in the persistence of antibodies to SARS-CoV-2 are unknown. We evaluated 32 the antibody response to SARS-CoV-2 in personnel from 10 healthcare facilities and its association 33 with individuals' characteristics and COVID-19 symptoms in an observational study. We enrolled 34 4735 subjects (corresponding to 80% of all personnel) for three time points over a period of 8-10 35 months. For each participant, we determined the rate of antibody increase or decrease over time in 36 relation to 93 features analyzed in univariate and multivariate analyses through a machine learning 37 approach. In individuals positive for IgG (≥ 12 AU/mL) at the beginning of the study, we found an 38 increase [p = 0.0002] in antibody response in symptomatic subjects, particularly with 39 anosmia/dysgeusia (OR 2.75, 95% CI 1.753 – 4.301), in a multivariate logistic regression analysis. 40 This may be linked to the lingering of SARS-CoV-2 in the olfactory bulb. 41

43 Introduction

44 It is becoming clear that the antibody response to SARS-CoV-2 can last at least 6 months in symptomatic patients ¹, but it seems to decline in asymptomatics ². Similarly, a reduction of 45 antibody response in asymptomatic individuals was shown in a study with a fewer number of 46 individuals $(n = 37)^{3}$. The antibody response in COVID-19 patients is associated with the 47 establishment of a memory B cell response which is higher at 6 months¹, however, it is not clear 48 49 whether there are features that correlate with this sustained B cell response. We previously showed 50 that an anti-SARS-CoV-2 serological analysis allowed us to follow the diffusion of the virus within healthcare facilities in areas differently hit by the virus ⁴. At 8-10 months of distance, we analyzed 51 52 the duration of this antibody response and evaluated whether there were features correlating with 53 maintenance, reduction or increase of the antibody response.

54

55 **Results**

56 We analyzed the persistence of the antibody response in healthcare workers that underwent 57 immunological surveillance for SARS-CoV-2 exposure and resulted positive for anti-Spike 1/2 IgG 58 $(IgG \ge 12 \text{ AU/mL})$. Although the test manufacturer considers positive subjects above 15 AU/mL 59 and equivocal those between 12 and 15 (AU/mL), based on our previous publication showing that these two groups behaved very similarly we considered positive everybody ≥ 12 AU/mL⁴. The 60 accrual was on a voluntary basis and did not occur in the symptomatic phase (at around 43 +/- 17 61 62 days from COVID-19 assessment when symptomatic). We excluded all of the individuals that 63 became positive over the course of the analysis so to focus only on those individuals that were 64 exposed during the first wave of infection to evaluate the duration of the antibody response. We 65 assessed the correlation of the rate of antibody increase or decrease with the different analyzed 66 features for the first two time points of observation in subjects with $IgG \ge 12$ AU/mL. In Tables 1 67 and 2 are reported the rates for individual classes of features with relative statistical analysis. As 68 shown, females sustained the antibody response better than males (p = 0.01); similarly non-medical 69 healthcare professionals (specifically, healthcare partner operators) had higher antibody rates (p =70 0.0009). The levels of antibodies increased in hospitals located in the Bergamo area (Castelli and 71 Gavazzeni p < 0.0001 (Table 1) which was more hit by COVID-19 (37 – 43% of individuals with $IgG \ge 12$)⁴. More important, the IgG rate in individuals which were positive for IgG (IgG ≥ 12) 72 73 AU/mL; n = 613) at the beginning of the study was increased (p < 0.000001) over time, and this 74 increase was either minor in asymptomatics (n = 91, p = 0.00003) and paucisymptomatics (n = 203) 75 or strong in symptomatics (n = 319, p = 0.0006) (Table 2). This may explain why individuals from 76 hospitals in the Bergamo area or non-medical healthcare professionals had higher levels of antibodies as most of them suffered from symptomatic COVID-19 (59% and 73%, respectively). On the contrary, those that had an intermediate IgG titer (3.8 < IgG < 12 AU/mL considered as negative) displayed all a significant reduction in IgG rate (p < 0.000001) (Table 1). However, this population is considered as negative for SARS-CoV-2 IgG according to manufacturer. Many symptoms, including fever, cough, muscle pain, asthenia, tachycardia and anosmia/dysgeusia, correlated with an increase of antibodies in the first two time points of observation (Table 2).

83 As we noticed that the distribution of the rate feature presented a high value of kurtosis (see methods) we restricted the data set to subjects with IgG rates either below the 10th percentile [< -84 (0.033 (n = 454)) or above the 90th percentile [> 0.005 (n = 445)] to prevent a bias-variance problem 85 in machine learning models. The accuracy of these rates was confirmed by a linear regression 86 87 analysis. In Figure 1a and 1b are shown the regression diagnostic plots of predicted values against 88 residuals of training and test data according to the threshold (< -0.033 AU/ml*day and > 0.00589 AU/ml*day). In Table 3 is shown the Chi-squared analysis for the populations below or above the 90 set threshold rates. We found that as for the previous analysis, males reduced the level of antibodies 91 more than females, even though this difference was no longer statistically significant (p = 0.06). 92 The levels of antibodies increased in hospitals located in the Bergamo area (Castelli and Gavazzeni: p = 0.0032 and p = 0.0005, respectively) which was more hit by COVID-19 (37 - 43% of 93 individuals with IgG \geq 12) and most of the individuals were symptomatic ⁴ while it decreased in 94 95 Humanitas Rozzano (p=0.0806) which was less heavily hit (10% of individuals with IgG \geq 12) and had less symptomatic individuals ⁴ (Table 3). The rate decreased in asymptomatic (65% of subjects 96 97 fell in the group < -0.033; p < 0.000001), remained constant in paucisymptomatic and increased in 98 symptomatic individuals (62% of subjects were in the group > 0.005; p < 0.00001) (Table 4). 99 Interestingly, among the different symptoms, fever, cough, muscle pain, asthenia, dyspnea, 100 tachycardia, chest pain and anosmia/dysgeusia all correlated with a higher number of individuals 101 falling into the group with rate > 0.005, indicating that these symptoms were strongly associated with sustained/increased antibody response (0.000001 , Table 4 and Suppl. Fig. 1).102 103 Among these, anosmia/dysgeusia was associated with the highest percentage of subjects presenting 104 with increased IgG rate (69%; p < 0.000001, Table 4 and Suppl. Fig. 1). Having observed 105 differences according to sex, role and site, and since many symptoms are linked, we performed a 106 multivariate statistical analysis based on a supervised machine learning classification approach (see 107 methods). Through a Bayesian hyperparameter optimization algorithm, we assessed that the best 108 machine learning model is a Bagging classifier of 7 logistic regression, which was evaluated both 109 on a training (Accuracy = 76.26; ROC AUC = 76.30; Recall = 81.14) and a test dataset (Accuracy = 110 72.00; ROC AUC = 72.12; Recall = 81.08), where the training/test split is 80%-20%, stratified by

111 outcome. Classification metrics on training set and test set are comparable, which shows that the 112 model does not present overfitting on training data. In Figure 1c is shown the multivariate logistic 113 regression analysis. We found that the increased rate was associated primarily with 114 anosmia/dysgeusia (regression coefficient=1.0, 95% CI 0.56 - 1.46) and with chest pain (regression 115 coefficient=0.84, 95% CI 0.24 - 1.44), while the decreased rate was associated to subjects with 116 intermediate IgG (3.8 < IgG < 12) (regression coefficient = -1.61, 95% CI -2.03 - -1.0), which may 117 be related to a noise in the instrument testing, and with past neoplasia (regression coefficient = -118 1.38, 95% CI -2.4 – -0.37). Interestingly, 54% of subjects with chest pain also presented loss of 119 smell/taste while only 22% of subjects with smell/taste dysfunction also had chest pain, suggesting 120 that IgG increase in the symptomatic population is primarily linked to anosmia and dysgeusia (not 121 shown). In figure 1d are shown the odds ratio relative to figure 1c, which for chest pain is 2.32 122 (95% CI 1.27 - 4.24), for anosmia/dysgeusia is 2.75 (95% CI 1.75 - 4.30), for subjects with 123 intermediate IgG (3.8 < IgG < 12) is 0.2 (95% CI 0.13 – 0.30) and for subjects with past neoplasia 124 is 0.25 (95% CI 0.09 - 0.69). Overall, these results indicate that although many symptoms are 125 associated with an increase of IgG abundance in the observation time, only anosmia/dysgeusia and 126 chest pain are associated to a higher IgG rate in the multivariate logistic regression analysis. By 127 contrast the population with past neoplasia or intermediate levels of IgG (3.8 < IgG < 12 AU/mL) 128 are the ones that display a reduction in IgG. However, the significance of the reduction in the 129 detection of antibodies in subjects with intermediate levels of IgG remains to be investigated, as this 130 population did not represent early infected individuals because they were all nasopharyngeal swab negative ⁴. 131

We then analyzed whether the antibody response was maintained over time in the third time point of analysis (n = 499) which was evaluated between November and December 2020 thus reaching an observation of 8-10 months. As shown in Figure 2 and Suppl. Fig. 2 we observed that both symptomatic and paucisymptomatic individuals still displayed a higher level of antibodies, however they did not increase between phase 2 and phase 3. By contrast, asymptomatic individuals did not increase their IgG levels over time.

138

139 **Discussion**

We analyzed the 8-10-month duration of an antibody response to SARS-CoV-2 in personnel from 9 healthcare facilities and an international medical school (Humanitas University) in Northern Italy in areas differently hit by the virus ⁴. We show that the antibody response is stable both in symptomatic and asymptomatic/paucisymptomatic individuals and is increased in females and in non-medical healthcare professionals. Previously, it has been shown in a study conducted in the 145 British population that the antibody response declines of nearly 22% in symptomatic individuals and of 64% in asymptomatic individuals². However, this study was based on a prick qualitative test 146 147 and thus the decline may be related to the sensitivity of the test. We also observed that the antibody 148 response declined when we analyzed the group (3.8 < IgG < 12 AU/mL) with IgG between the limit of detection (3.8 AU/mL) and the threshold of positivity (IgG \geq 12 AU/mL), as set by 149 150 manufacturer. Whether this is linked to a difference linked to the sensitivity of the test or to a real 151 reduction in an antibody response that may or may not be specific to SARS-CoV-2, remains to be 152 established. In a previous analysis we excluded that this population represented individuals in the 153 initial phases of an infection as all of them were tested for SARS-CoV-2 by a nasopharyngeal swab 154 which however resulted negative⁴. When we analyzed the extremes, i.e. the individuals with higher rates of antibody increase or decrease (< -0.033 and > 0.005 AU/mL*day) we observed that 155 156 asymptomatics had higher negative rates while symptomatics tended to continue increasing the 157 antibody levels suggesting that extreme changes in rate separate the symptomatics from the 158 asymptomatics. As during the observation time there was very limited viral diffusion in Northern 159 Italy, as confirmed also by the finding that only 2 individuals became IgG positive and 2981 160 remained IgG negative throughout the study (all excluded from the analysis), we can conclude that 161 the sustained or augmented antibody response may not be linked to a re-exposure to the virus. In an 162 attempt to address what improved the antibody response, we found that several symptoms were 163 associated to increased rates of antibodies, however, in a multivariate logistic analysis only 164 anosmia/dysgeusia and chest pain were linked with the highest regression coefficients. Chest pain and anosmia are long-lasting symptoms in COVID-19 patients ⁵. In addition, anosmia and/or 165 dysgeusia are very common as they are found in around 50-70% of subjects affected by COVID-19 166 ^{6,7}. In our cohort (Table 2), 49% of IgG positive subjects had anosmia/dysgeusia, 28% chest pain 167 168 and 13.7% both anosmia/dysgeusia and chest pain, suggesting that indeed these two symptoms 169 may, either alone or in combination, associate with IgG increase. We and others previously found 170 that anosmia/dysgeusia together with fever were the symptoms that mostly characterized SARS-CoV-2 exposure ^{4, 8}. In agreement, anosmia and dysgeusia have been proposed to be used to track 171 SARS-CoV-2 diffusion ⁹. Interestingly, SARS-CoV-2 can infect the olfactory epithelium ^{10, 11}, 172 173 including olfactory sensory neurons, support cells and immune cells, that express the viral entry receptors ACE2 and TMPRSS2^{10, 12, 13}. Here, the virus can persist long and induce local 174 inflammation ¹¹ and olfactory bulb abnormalities ^{14, 15, 16}. In agreement, the loss of smell and taste 175 176 can persist in individuals even with RT-PCR SARS-CoV-2 negativity in the nasopharyngeal swab for months ^{11, 17}. Supporting this possibility, we did not detect any further increase of IgG levels 177

between phase 2 and phase 3 suggesting that when individuals eliminate the virus then there is nofurther increase of the antibody response.

One limitation of our study is that we followed our healthcare workers for the exposure to SARS-CoV-2 via measuring the anti S1/S2 IgG response and have not evaluated any other antibody subtype nor their neutralizing activity, even though the test used has correlated the antibody levels with their neutralizing activity, as reported in the methods section.

- 184 Overall, these data suggest that increased antibody response in patients with anosmia/dysgeusia may be linked to persistence of the virus in the olfactory bulb which through local inflammation 185 186 and release of antigens, maintains and boosts the antibody response. This study opens new 187 perspectives on the immunity to SARS-CoV-2 and warrants further investigation on the role of 188 anosmia/dysgeusia on antibody response through the design of prospective observational studies 189 coupling the testing of SARS-CoV-2 persistence in the olfactory bulb, loss of smell or taste and 190 antibody titers. In addition, we show that the antibody response to the natural infection is durable 191 and persists for at least 8 months. If the antibody response elicited by the vaccines is similarly 192 effective, we may expect it to last for at least the same amount of time. Further, this observation 193 strongly supports our findings and those of others that convalescent symptomatic COVID-19 patients should receive only one dose of vaccine ^{18, 19, 20, 21} and suggests that this may occur even at 194 195 months of distance from developing the disease as their antibody response will just need to be 196 boosted.
- 197

198 Methods

199 Study population

200 This observational study has been approved by the international review board of Istituto Clinico Humanitas for all participating institutes (clinicaltrial.gov NCT04387929). Accrual was on a 201 voluntary basis: it started on April 28^{th} and more than 80% of personnel participated (n = 4735). 202 203 The study foresees 4 blood collections every 3/4 months. 10 different centers participate: Istituto 204 Clinico Humanitas (ICH), Rozzano (MI); Humanitas Gavazzeni, Bergamo; Humanitas Castelli, 205 Bergamo; Humanitas Mater Domini (HMD), Castellanza (VA); Humanitas Medical Center, HMC, 206 Varese; Humanitas University, Pieve Emanuele (MI); Humanitas San Pio X, Milano; Humanitas 207 Cellini, Torino; Humanitas Gradenigo, Torino; Clinica Fornaca, Torino. All participants signed an 208 informed consent and filled a questionnaire before blood collection. We analyzed 93 features (72 209 categorical and 17 numerical and 4 temporal) including, age, sex, location, professional role, time 210 between sample collections, COVID-19 symptoms (fever, sore throat, cough, muscle pain, asthenia, 211 anosmia/dysgeusia (loss of smell and taste), gastrointestinal symptoms, conjunctivitis, dyspnea,

212 chest pain, tachycardia, pneumonia), home exits and smart-working, comorbidities (diabetes, 213 asthma, neoplasia, autoimmunity, cardiovascular disorders, hepatic disorders). We considered 214 "asymptomatics" subjects without any symptoms; "paucisymptomatics" individuals that developed 215 1 or 2 symptoms; "symptomatics" individuals with more than 3 symptoms. None of the participants 216 were enrolled at the time of symptoms. Thus, when the serological test was performed, they were 217 either asymptomatics or the symptoms had disappeared. After excluding for employees that became 218 positive for SARS-CoV-2 IgG (n = 2) during the observation period and those that dropped from 219 phase 1 or for which we were missing at least two features, we analyzed 4534 participants (4.25% 220 drop out). Here we show the results of the end of phase 2 and phase 3 (second and third blood 221 sampling).

222

IgG measure

224 For the determination of IgG anti SARS-CoV-2, the Liaison SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Saluggia (VC), Italy) was used ²². The method is an indirect chemiluminescence 225 226 immunoassay for the determination of anti-S1 and anti-S2 specific antibodies. According to kit 227 manufacturer, the test discriminates among negative (< 15 AU/mL; with 3.8 as the limit of IgG 228 detection) and positive (≥ 15 AU/mL) subjects. We considered positive subjects with IgG plasma 229 levels \geq 12 AU/mL rather than those with IgG \geq 15 AU/mL, as suggested by the test manufacturer, 230 based on our previous publication showing that these two groups behaved very similarly ⁴. In 231 addition, we considered also individuals with IgG comprised between 3.8 and 12 AU/mL (which 232 we called IgG med: 3.8 < IgG < 12 AU/mL). Consistency and reproducibility of the antibody test in 233 samples collected in the two time points was confirmed for a limited number of individuals (n = 50)234 displaying different degrees of IgG positivity. The LIAISON assay's performance in comparison to a microneutralization assay is shown in Bonelli et al.²². The LIAISON serological S1/S2 assay can 235 236 distinguish between neutralization positive and negative samples at cut-offs near 15 AU/mL, and 237 additionally the data indicate that 92% of the samples with >80 AU/mL had neutralization 238 titers \geq 1:80, while 87% of samples with >80 AU/mL had neutralization titers \geq 1:160.

As the samples were analyzed in separate batches, we compared the test accuracy on 21 samples from the phase 1 with the detection kits of phase 1 and phase 2 and demonstrated that the tested IgG were almost over-imposable (Suppl. Fig. 3).

242

243 Statistical analysis and model

We first cleared the dataset by eliminating data from all of those subjects that did not develop an IgG response over time (IgG \leq 3.8 at the beginning and at the end of the examination) (n = 2981). We then analyzed the rate of antibody response defined as:

247

248 $RATE = IgG \ phase \ II - IgG \ phase \ I = [AU \ /mL * day]$

249 250 $\Delta days$

Positive rates mean increased antibody response, while negative rates indicate reduction of antibody
response between the two analyzed time points.

For statistical analysis, we performed both a univariate and a multivariate analysis. We applied Wilcoxon-Mann-Whitney statistical non-parametric test to compare the antibody rate distribution between classes of subjects (Table 1 and Table 2).

256 We analyzed the distribution of the rate feature and found a high value of kurtosis (461) around the 257 median value of 0.016, hence to perform a multivariate analysis we restricted the data set to subjects with IgG rates either below the 10th percentile or above the 90th percentile to prevent a 258 259 bias-variance problem in machine learning models and subjected the data to a linear regression 260 analysis between the training and test data sets, where the target variable (rate of antibodies) was standardized using the Yeo-Johnson method²³. We then applied Chi-squared statistical test to 261 262 evaluate differences between classes and the rate thresholds described above (Tables 3 and 4). In 263 order to evaluate the possible interactions between features and the rate of antibody response, we 264 developed a multivariate approach to perform a binary classification between subjects who 265 increased or decreased the level of antibodies. A set of 7 logistic regressions has been applied on 266 data using a bootstrap procedure (samples are drawn with replacement) and the output of each 267 classifier has been averaged by a Bagging classifier to obtain the final output. The selection of 268 hyperparameters of the machine learning model and the feature selection has been performed with a 269 Bayesian optimization approach based on cross validation (4 folds, stratified by outcome). The 270 comparisons shown in Figure 2 and Suppl. Fig. 2 were carried out using one-tailed Wilcoxon 271 matched-pairs signed rank test. A probability value of P < 0.05 was considered significant. Data 272 analyses were carried out using GraphPad Prism version 8 and Python version 3.8 with the 273 following libraries: Pandas (version 1.1.4, data wrangling), Scipy (version 1.3.2, statistical 274 analysis), Scikit-Learn (version 0.24.1, LR statistical model).

275

276 Data and code availability

Humanitas metadata are deposited in Institutional Zenodo community named IRCCS Humanitas
Research Hospital & Humanitas University. The dataset and the code are available at the link
https://zenodo.org/record/4528974#.YCONKXnSJaQ with restricted license however available
upon request.

281

282 **References**

283 Acknowledgments

This work was partially supported by a philantropic donation by Dolce & Gabbana, by the ItalianMinistry of Health (Ricerca corrente) and by Fondazione Humanitas per la Ricerca.

We would like to thank all the employees that volunteered to participate to this study, all the nurses and personnel that collected the samples and the laboratory technicians that run the serological and rinopharyngeal tests. We would also like to thank the Humanitas management and staff, Drs Patrizia Meroni, Michele Lagioia and Michele Tedeschi, who warmly supported this study for the safety of the employees.

291

292 Author contribution

R.L. and L.U.: performed data analysis; C.P.: contributed to data analysis and manuscript writing;
G.A. and V.S.: contributed to data analysis; M.T.S.: coordinated and supervised the laboratory
analyses; E.A.: coordinated the recruitment and sampling of subjects (project administration) and
participated in clinical study design; M.S.: carried out the laboratory analyses; A.M.:
conceptualization and funding acquisition; M.R.: conceived the study, analyzed the data and wrote
the manuscript.

299

300 Competing interests

- 301 The authors declare no competing interests.
- 302
- 303

304 Tables

305 Table 1. Demographic distribution of antibody rates.

		counts	min	25 perc	50 perc	75 perc	max	mean	St.Dev.	p_value ^a
a	F	1105	-3.39	-0.04	-0.02	0.02	16.32	0.07	0.61	0.0120
Sex	М	448	-0.88	-0.04	-0.02	0	10.37	0.03	0.53	0.0139
	21-30	300	-3.39	-0.04	-0.02	0.01	4.51	0.03	0.41	0.2644
-	31-40	365	-0.92	-0.04	-0.02	0.01	2.26	0.02	0.21	0.2302
Age	41-50	455	-2.49	-0.04	-0.02	0.03	3.11	0.06	0.37	0.1083
-	51-60	309	-0.88	-0.04	-0.01	0.02	16.32	0.1	0.96	0.1442
-	60+	124	-0.68	-0.04	-0.02	-0.01	10.37	0.12	0.99	0.0586
	18.5≤ BMI <25	940	-0.92	-0.04	-0.02	0.01	10.37	0.03	0.41	0.3821
DMTP	$BMI \ge 30$	106	-3.39	-0.05	-0.02	0.14	16.32	0.23	1.69	0.2182
BMI ^b	25≤ BMI <30	347	-0.57	-0.04	-0.02	0.01	3.11	0.05	0.29	0.3933
-	BMI < 18.5	73	-0.22	-0.04	-0.02	0.02	1.27	0.05	0.26	0.3959
	$IgG \ge 12$	613	-3.39	-0.08	0.02	0.23	16.32	0.18	0.92	2.1 E-10
IgG class	$IgG \le 3.8$	74	0.01	0.01	0.02	0.03	0.08	0.02	0.01	1.5 E-15
phase 1	3.8 < IgG < 12	866	-0.13	-0.03	-0.02	-0.01	0.83	-0.02	0.04	8.0 E-22
	Other ^c	200	-0.57	-0.04	-0.02	-0.01	16.32	0.09	1.17	0.0116
-	Anesthesiologist	19	-0.83	-0.04	-0.02	0.01	0.09	-0.05	0.2	0.4305 ^b
-	Biologist	18	-0.18	-0.05	-0.02	-0.02	0.03	-0.04	0.05	0.0978 ^b
-	Surgeon	67	-0.88	-0.05	-0.02	0.07	0.61	0.02	0.21	0.2653
Role	Physiotherapist	21	-0.12	-0.04	-0.02	0.01	0.35	0.01	0.1	0.4204
	Nurse	398	-3.39	-0.04	-0.02	0.04	3.11	0.08	0.41	0.0581
	Physician	210	-0.92	-0.04	-0.01	0.02	10.37	0.08	0.75	0.0804
	Healthcare Partner Operator	149	-2.49	-0.03	-0.01	0.17	1.55	0.1	0.38	0.0009
	Front office (PARC)	108	-0.32	-0.04	-0.02	0.01	2.55	0.03	0.27	0.2892
	Researcher	50	-1.5	-0.03	-0.02	-0.01	4.51	0.06	0.68	0.1514
	Cleaning service	29	-0.65	-0.03	-0.02	0.03	1.72	0.09	0.41	0.2414
	Transport service	14	-0.39	-0.04	-0.01	0.02	2.22	0.13	0.62	0.4359 ^b
	Staff	188	-0.4	-0.04	-0.02	-0.01	0.98	0	0.15	0.0026
-	Student	20	-0.19	-0.03	-0.02	-0.01	0.21	-0.02	0.08	0.3705 ^b
	Laboratory technician	31	-0.17	-0.03	-0.01	-0.01	0.51	0.02	0.15	0.3243
	Radiology technician	31	-0.18	-0.03	-0.02	0.01	1.01	0.04	0.22	0.4002
	Other ^c	21	-0.19	-0.04	-0.02	-0.01	2.22	0.08	0.49	0.2080
-	Casa di Cura Cellini	51	-0.17	-0.05	-0.03	-0.01	1.27	0.01	0.22	0.0111
Site	Clinica Fornaca di Sessant	47	-0.4	-0.05	-0.03	0	0.53	0	0.15	0.0833
	Humanitas Castelli	87	-0.28	-0.04	0.02	0.21	3.11	0.24	0.62	4.7 E-05
	Humanitas Gavazzeni	313	-0.88	-0.04	-0.01	0.15	10.37	0.13	0.68	0.0001
	Humanitas Gradenigo	109	-2.49	-0.04	-0.02	-0.01	0.67	-0.01	0.27	0.0586
	Humanitas Mater Domini	105	-0.17	-0.03	-0.02	-0.01	0.63	0	0.1	0.3412
	Humanitas Medical Care	23	-0.19	-0.04	-0.02	-0.01	0.02	-0.03	0.04	0.0969
	Humanitas Rozzano	667	-3.39	-0.04	-0.02	0	16.32	0.04	0.7	0.0338
	Humanitas San Pio X	98	-0.68	-0.03	-0.02	0	2.39	0.04	0.29	0.2968
	Humanitas University	32	-0.2	-0.04	-0.02	-0.01	0.19	-0.03	0.08	0.0590

^a = Wilcoxon-Mann-Whitney test

^b = Some subjects did not indicate their BMI

c = Refers to volunteers and other professionals that operate in several structures

d = Minority class is less or equal to 20 (Wilcoxon-Mann-Whitney test is not reliable)

Table 2. Antibody rates according to symptoms.

			counts	min	25 perc	50 perc	75 perc	max	mean	St. Dev.	p_value ^a
Class symptoms	Asymptomatic		91	-1.5	-0.13	-0.05	0.09	2.39	0.04	0.5	0.00003
phase 1 (subjects with $IgG \ge 12$)	Paucisymptomatic		203	-3.39	-0.08	0.02	0.21	4.51	0.14	0.56	0.32865
with $1gO \ge 12$	Symptomatic	319	-2.49	-0.06	0.07	0.28	16.32	0.24	1.16	0.00057	
	Fever	No	350	-3.39	-0.09	0.01	0.21	4.51	0.13	0.02725	0.02725
	rever	Yes	263	-2.49	-0.06	0.05	0.25	16.32	0.24		
	Low-grade fever	No	481	-3.39	-0.08	0.02	0.23	16.32	0.19	0.17265	0.17265
	Low-grade level	Yes	132	-0.39	-0.07	0.05	0.26	2.55	0.14		0.17200
	Cough	No	372	-3.39	-0.08	0.01	0.19	16.32	0.14	0.01120	0.01120
	Cough	Yes	241	-2.49	-0.07	0.07	0.31	10.37	0.24		0.01120
	Sore throath	No	353	-3.39	-0.09	0.02	0.23	16.32	0.19	0.08309	0.08309
	Sore throath	Yes	260	-2.49	-0.07	0.04	0.25	4.51	0.16		
	Muscle pain	No	299	-1.5	-0.1	0	0.2	4.51	0.13	0.00763	0.00763
		Yes	314	-3.39	-0.06	0.06	0.27	16.32	0.22		
	Asthenia	No	341	-3.39	-0.1	0	0.21	16.32	0.17	0.00574	0.00574
		Yes	272	-2.49	-0.06	0.07	0.25	10.37	0.19		
Symptoms phase 1 (subjects with	Anosmia / dysgeusia	No	313	-3.39	-0.12	-0.01	0.2	16.32	0.14	0.00006	0.00006
I (subjects with $IgG \ge 12$)		Yes	300	-0.86	-0.05	0.06	0.28	10.37	0.22		
150 - 12)	Gastrointestinal symptoms	No	403	-3.39	-0.08	0.03	0.21	10.37	0.17	0.46477	0.46477
		Yes	210	-2.49	-0.08	0.02	0.25	16.32	0.19		
		No	517	-3.39	-0.08	0.02	0.21	16.32	0.18	0.16050	0.16050
	Conjunctivitis	Yes	96	-2.49	-0.07	0.04	0.32	1.72	0.14		
	Duonnaa	No	493	-3.39	-0.08	0.02	0.23	16.32	0.16	0.34700	0.34700
	Dyspnea	Yes	120	-2.49	-0.07	0.05	0.26	10.37	0.24		
	Chest pain	No	502	-3.39	-0.08	0.01	0.24	10.37	0.15	0.08088	0.08088
		Yes	111	-0.39	-0.04	0.07	0.22	16.32	0.3		
	Tachycardia	No	512	-3.39	-0.08	0.01	0.21	4.51	0.13	0.02353	0.02353
		Yes	101	-2.49	-0.06	0.08	0.32	16.32	0.4		
	Du anum anis	No	568	-3.39	-0.08	0.02	0.22	16.32	0.15	0.18692	0.18692
	Pneumonia	Yes	45	-0.88	-0.06	0.06	0.38	10.37	0.51	1.69	
^a = Wilcoxon-Mar	nn-Whitney test										

		< 10 perc	>90 perc	p_value
Sex	F	321	340	0.0627
Sex	М	133	105	0.0627
	21-30	93	83	0.5429
	31-40	108	94	0.3804
Age	41-50	121	142	0.0970
	51-60	88	98	0.3711
	60+	44	28	0.0793
	$18.5 \leq BMI < 25$	267	255	0.6963
D) (T å	$BMI \ge 30$	58	72	0.1750
BMI ^a	25≤ BMI <30	106	93	0.4214
	BMI < 18.5	23	25	0.8261
	Other ^b	63	37	0.0109
	Anesthesiologist	6	7	0.9701
	Biologist	5	2	0.4640
	Surgeon	25	21	0.7007
	Physiotherapist	6	7	0.9710
	Nurse	113	132	0.1255
	Physician	56	61	0.6082
Role	Healthcare Partner Operator	38	64	0.0062
	Front office (PARC)	31	28	0.8494
	Researcher	13	9	0.5485
	Cleaning service	7	9	0.7698
	Transport Service	5	5	0.7747 ^c
	Staff	69	44	0.0214
	Student	5	4	0.9759 ^c
	Laboratory Technician	6	7	0.9701
	Radiology Technician	6	8	0.7587
	Other ^b	6	3	0.5223 °
	Casa di Cura Cellini	19	8	0.0573
	Clinica Fornaca di Sessant	18	12	0.3828
	Humanitas Castelli	23	47	0.0032
Site	Humanitas Gavazzeni	97	142	0.0005
	Humanitas Gradenigo	36	22	0.0918
	Humanitas Mater Domini	20	23	0.7041
	Humanitas Medical Care	8	3	0.2379°
	Humanitas Rozzano	190	160	0.0806
	Humanitas San Pio X	27	21	0.5025
	Humanitas University	10	4	0.1905°
^a = Som	e subjects did not indicate their			0.1700

326 Table 3. Chi-squared analysis of groups $< 10^{th}$ percentile and $> 90^{th}$ percentile	
---	--

^b = Refers to volunteers and other professionals that operate in several structures ^c = Minority class is less or equal to 5 (chi-square test is not reliable)

	E.	No	<10perc 360	>90perc 284	p_value	% Yes<10 perc ^a	%Yes>90p
	Fever	Yes	94	161	3.9E-07	37	63
		No	388	359		0,	00
	Low-grade fever	Yes	66	86	0.0678	43	57
		No	335	284			
	Cough	Yes	119	161	0.0016	43	58
		No	302	271	0.0000		
	Sore throath	Yes	152	174	0.0923	47	53
		No	310	246	0.0004		
	Muscle pain	Yes	144	199	0.0001	42	58
		No	340	268	2.75.07		
	Asthenia	Yes	114	177	3.7E-06	39	61
		No	364	247	4.017 1.5		
	Anosmia/dysgeusia	Yes	90	198	4.0E-15	31	69
Symptoms	Gastrointestinal	No	336	313	0.0405		
• •	symptoms	Yes	118	132	0.2485	47	53
		No	400	382	0.2622		
	Conjunctivitis	Yes	54	63	0.3633	46	54
	D	No	405	375	0.0270		
	Dyspnea	Yes	49	70	0.0370	41	59
	Chast nois	No	415	367	0.0001		
	Chest pain	Yes	39	78	0.0001	33	67
	Tachycardia	No	406	371	0.0107		
	Tachycardia	Yes	48	74	0.0107	39	61
	D	No	440	420	0.0000		
	Pneumonia	Yes	14	25	0.0889	36	64
	Total of Symptoms	Asymptomatic	150	80	3.4E-07	65	35
	Total of Symptoms in phase I	Paucisymptomatic	179	158	0.2520	53	47
	-	Symptomatic	125	207	5.6E-09	38	62
	Chronic Obstructive	No	451	444	0.6305 ^b		
	Bronchopneumopathy	Yes	3	1	0.0303		
	Asthma	No	430	412	0.2408		
	Astillia	Yes	24	33	0.2408		
	Dyslipidemia	No	413	404	0.9834		
	Dyshpideinia	Yes	41	41	0.7054		
	Past Neoplasia	No	431	438	0.0063		
	i ast incopiasia	Yes	23	7	0.0005		
	Hypertension	No	401	409	0.0915		
		Yes	53	36	0.0715		
	Past	No	454	443	0.4702 ^b		
	Coronaropathies	Yes	0	2	0.4702		
	Atrial Fibrillation	No	450	441	0.7439 ^b		
	. tanai i formation	Yes	4	4			
Comorbidities	Past Stroke/ TIA	No	452	445	0.4878 ^b		
comoroidines	Tust Strokey TIA	Yes	2	0			
	Steatosis/Cyrrosis	No	448	444	0.1359 ^b		
		Yes	6	1			
	Chronic kidney	No	453	445	0.9920 ^b		
	failure	Yes	1	0			
	Other liver diseases	No	452	441	0.6641 ^b		
		Yes	2	4	5.5071		
	Rheumatological	No	445	431	0.3715		
	diseases	Yes	9	14	0.5715		
	Otherdiseases	No	418	409	0.9726		
	of the immune system	Yes	36	36	0.7720		
	Diabetes mellitus	No	452	443	0.6305 ^b		
	Diabetes menitus	Yes	2	2	0.0303		
	Gotta	No	452	445	0.4878 ^b		
		Yes	2	0	0.40/0		

329 Table 4. Chi-squared analysis of groups $< 10^{th}$ percentile and $> 90^{th}$ percentile per symptoms.

333 Figure legends

334

Figure 1: a, Dataset < 10th percentile Regression Diagnostic plot of amount of IgG after Yeo-Johnson normalization against residuals of training and test data; b, Dataset >90th percentile
Regression Diagnostic plot of amount of IgG after Yeo-Johnson normalization against residuals of
training and test data; c, Barplot with Logistic Regression coefficients for most important features;
d, Odds ratio of Logistic Regression with confidence intervals (95%) for the most important
features.

341

Figure 2: Anti-Spike S1/S2 IgG plasma levels in asymptomatics (n=61), paucisymptomatics (n=163) and symptomatics (n=275) measured at three different time points (phase 1-3). Each dot corresponds to an individual subject. Log scale on Y axis. The box plots show the interquartile range, the horizontal lines show the median values and the whiskers indicate the minimum-tomaximum range. *P* values were determined using one-tailed Wilcoxon matched-pairs signed rank test.

348

349 **References**

350

- Dan JM, *et al.* Immunological memory to SARS-CoV-2 assessed for up to 8 months after
 infection. *Science* 371, (2021).
- 3532.Ward H, *et al.* Declining prevalence of antibody positivity to SARS-CoV-2: a community354study of 365,000 adults. *medRxiv*, 2020.2010.2026.20219725 (2020).
- 355 3. Long QX, *et al.* Clinical and immunological assessment of asymptomatic SARS-CoV-2
 356 infections. *Nat Med* 26, 1200-1204 (2020).
- Sandri MT, *et al.* SARS-CoV-2 serology in 4000 health care and administrative staff across
 seven sites in Lombardy, Italy. *Sci Rep* 11, 12312 (2021).
- S. Carfi A, Bernabei R, Landi F, Group ftGAC-P-ACS. Persistent Symptoms in Patients After
 Acute COVID-19. *JAMA* 324, 603-605 (2020).

Butowt R, von Bartheld CS. Anosmia in COVID-19: Underlying Mechanisms and
 Assessment of an Olfactory Route to Brain Infection. *Neuroscientist*, 1073858420956905

- 362Assessment of an Olfactory Route to Brain Infection. Neuroscientist, 1073858420956905363(2020).
- 364 7. Lechien JR, *et al.* Clinical and epidemiological characteristics of 1420 European patients
 365 with mild-to-moderate coronavirus disease 2019. *J Intern Med* 288, 335-344 (2020).
- Kumar N, Bhartiya S, Desai S, Mutha A, Beldar A, Singh T. Seroprevalence of Antibodies
 Against SARS-CoV-2 Among Health Care Workers in Mumbai, India. *Asia Pac J Public Health*, 1010539520977307 (2020).
- 9. Pierron D, *et al.* Smell and taste changes are early indicators of the COVID-19 pandemic
 and political decision effectiveness. *Nat Commun* 11, 5152 (2020).

371	10.	Brann DH, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory
372		system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv 6, (2020).
373	11.	De Melo GD, et al. COVID-19-related anosmia is associated with viral persistence and
374		inflammation in human olfactory epithelium and brain infection in hamsters. Sci Transl
375		<i>Med</i> , (2021).
376	12.	Bilinska K, Jakubowska P, Von Bartheld CS, Butowt R. Expression of the SARS-CoV-2
377		Entry Proteins, ACE2 and TMPRSS2, in Cells of the Olfactory Epithelium: Identification of
378		Cell Types and Trends with Age. ACS Chem Neurosci 11, 1555-1562 (2020).
379	13.	Chen M, <i>et al.</i> Elevated ACE-2 expression in the olfactory neuroepithelium: implications
380		for anosmia and upper respiratory SARS-CoV-2 entry and replication. Eur Respir J 56,
381		(2020).
382	14.	Politi LS, Salsano E, Grimaldi M. Magnetic Resonance Imaging Alteration of the Brain in a
383		Patient With Coronavirus Disease 2019 (COVID-19) and Anosmia. JAMA Neurol 77, 1028-
384		1029 (2020).
385	15.	Tsivgoulis G, et al. Olfactory bulb and mucosa abnormalities in persistent COVID-19-
386		induced anosmia: a magnetic resonance imaging study. Eur J Neurol, (2020).
387	16.	Laurendon T, et al. Bilateral transient olfactory bulb edema during COVID-19-related
388		anosmia. <i>Neurology</i> 95 , 224-225 (2020).
389	17.	Yan CH, Prajapati DP, Ritter ML, DeConde AS. Persistent Smell Loss Following
390		Undetectable SARS-CoV-2. Otolaryngol Head Neck Surg 163, 923-925 (2020).
391	18.	Krammer F, et al. Antibody Responses in Seropositive Persons after a Single Dose of
392		SARS-CoV-2 mRNA Vaccine. N Engl J Med 384, 1372-1374 (2021).
393	19.	Saadat S, et al. Binding and Neutralization Antibody Titers After a Single Vaccine Dose in
394		Health Care Workers Previously Infected With SARS-CoV-2. JAMA 325, 1467-1469
395		(2021).
396	20.	Abu Jabal K, et al. Impact of age, ethnicity, sex and prior infection status on
397		immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-
398		world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro
399		<i>Surveill</i> 26 , (2021).
400	21.	Levi R, et al. One dose of SARS-CoV-2 vaccine exponentially increases antibodies in
401		recovered individuals with symptomatic COVID-19. J Clin Invest, (2021) in press.
402	22.	Bonelli F, et al. Clinical And Analytical Performance Of An Automated Serological Test
403		That Identifies S1/S2 Neutralizing IgG In COVID-19 Patients Semiquantitatively. J Clin
404		Microbiol, (2020).
405	23.	Yeo IK, Johnson RA. A new family of power transformations to improve normality or
406		symmetry. <i>Biometrika</i> 87, 954-959 (2000).
407		
408		



